List of Studies ( Metabolite:Thr-Thr-Ala)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004194 | AN006966 | PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003565 | AN005858 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003179 | AN005222 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Pseudomonas aeruginosa | Monash Institute of Pharmaceutical Sciences | LC-MS | |
| ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
